Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.63 |
| ▸ | HTR2A | P28223 | 14/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8959629 | 0.88 | HTR2C (0.56) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8959641 | 0.88 | HTR2C (0.56) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9233642 | 0.88 | HTR2C (0.78) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL26674263 | 0.83 | HTR2C (0.50) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24143180 | 0.83 | HTR2C (0.65) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15307684 | 0.81 | HTR2C (0.78) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24143095 | 0.81 | HTR2C (0.63) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25689136 | 0.79 | HTR2C (0.65) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| Fumaric Acid SCHEMBL8959658 | 0.78 | HTR2C (0.62) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| Fumaric Acid SCHEMBL8959645 | 0.78 | HTR2C (0.62) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | HTR2C 3626/4885HTR2A 3630/4885CYP1A2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.